Chris, fair assessment and from where I sit I'd say Summit was rather well placed (as long as it works).
Summit - phase 2 shortly. 1st results end 2016 Biomarin - major FDA setback (unlikely to get approval IMO) Sarepta - major FDA setback (likely to require larger study IMO. Under way I think) Santhera - looks OK but is not a cure but treatment, so potential for combi use PTC Therapeutics - doubt would get FDA approval without more trials. Of limited benefit. Pfizer- not a cure but treatment. phase 2 results 2018 FibroGen - not a cure but treatment. phase 2 results 2018 (non walking boys so different target) Akashi - major setback. Trial on hold. Safety issues Catabasis - not a cure but treatment, so potential for combi. Phase 2 starting later 2016 Capricor - not a cure and on the wilder side of treatments. Phase 1
Yep, we seem to be a rising stock again. I guess people realise it's now very oversold and there is huge upside for traders. Obviously investors know there is a massive upside from here.... just need to wait for the news flow and the science/business chaps to work their magic. GLA
I agree with Free-Money on his thoughts on C-Diff and DMD as it is exactly how I think it will pan out.
I remember Glynn saying at one of the meetings that if C-Diff at phase 2 was positive it could take up to 6 months to come up with a deal but before that we await an update on C-Diff on the nature of the strains encountered.
At the conference call on C-Diff Glynn said that they had high level results but not the detail as to which strains of C-Diff had been 'defeated' but that the trials in the USA and Canada were hopefully sufficiently wide spread to have caught some of them hence the design of the trials. I believe that Summit thinks that statistically they should have caught some of the more virulent strains.
Fingers crossed for positive news this quarter on DMD and C-Diff.
With regards the current SP as I have said before they are currently as 'Cheap as chips' - in my opinion worth a punt.
Finally I am looking forward to the AGM at which there will be many questions not sure about the champagne.
Datafeed and UK data supplied by NBTrader and Digital Look.
While London South East do their best to maintain the high quality of the information displayed on this site,
we cannot be held responsible for any loss due to incorrect information found here. All information is provided free of charge, 'as-is', and you use it at your own risk.
The contents of all 'Chat' messages should not be construed as advice and represent the opinions of the authors, not those of London South East Limited, or its affiliates.
London South East does not authorise or approve this content, and reserves the right to remove items at its discretion.